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Abstract: Personalized medicine (PM), included in P5 medicine (Personalized, Predictive, Preventive, 
Participative and Precision medicine) is an innovative approach to the patient, emerging from the need 
to tailor and to fit the profile of each individual. PM promises to dramatically impact also on forensic 
sciences and justice system in ways we are only beginning to understand. The application of omics (ge-
nomic, transcriptomics, epigenetics/imprintomics, proteomic and metabolomics) is ever more funda-
mental in the so called “molecular autopsy”. Emerging fields of interest in forensic pathology are repre-
sented by diagnosis and detection of predisposing conditions to fatal thromboembolic and hypertensive 
events, determination of genetic variants related to sudden death, such as congenital long QT syn-
dromes, demonstration of lesions vitality, identification of biological matrices and species diagnosis of a 
forensic trace on crime scenes without destruction of the DNA. The aim of this paper is to describe the 
state-of-art in the application of personalized medicine in forensic sciences, to understand the possibili-
ties of integration in routine investigation of these procedures with classical post-mortem studies and to 
underline the importance of these new updates in medical examiners’ armamentarium in determining 
cause of death or contributing factors to death. 
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1. INTRODUCTION 
1.1. Personalized Medicine and Molecular Autopsy 
 Personalized medicine (PM), included in so called P4 
medicine (Personalized, Predictive, Preventive and Participa-
tive medicine), besides a fifth P represented by emerging 
Precision medicine initiative, is an innovative approach to 
the patient, in a comprehensive effort integrated in the com-
mon frame of P5 medicine. As a result, rather than accepting 
the one-size-fits-all, the need to be tailored to fit the profile 
of each individual patient is an emerging practice [1]. In this 
way, new approaches are critical to adapt clinical treatment 
to the individual and to propose available alternatives taking 
into account the specific profile of the person. In other 
words, clinical practice, by translation of the general ad-
vances in scientific knowledge and implementation of new 
diagnostics, can finally and successfully lead to tailoring and 
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personalization, offering better-targeted diagnosis and treat-
ments (diagnostic and therapeutic - also together “theragnos-
tic”). Theragnostics, in fact, is a treatment strategy that com-
bines therapeutics with diagnostics, associating diagnostic 
tests that identify patients to be helped by a medication, and 
targeted drug therapy based on the test results [2]. The final 
aim is to develop efficient targeted therapies with adequate 
benefit/risk to patients and a better molecular understanding 
of how to optimize drug appropriateness-efficacy-safety, 
monitoring the response to the treatment and eliminating the 
unnecessary ones. 
 On the other hand, even if clinical acceptance has been 
proven as slow and all these clinical applications seem actu-
ally entangled, PM promises to dramatically impact also the 
justice system in ways we are only beginning to understand. 
It is clear that the application of personalized medicine in the 
practice of law, in general, and in the autopsy practice, in 
particular, is of great medico-legal interest and may have 
potential legal consequences [3]. Moreover, PM’s forensic 
pathology ramifications are evident and, as an analogue of 
PM, a new essential aspect of this approach has emerged, so 
called personalized justice (PJ) as application of post-mortem 
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PM in medico-legal investigation [4]. In fact, besides classic 
forensic tools such as toxicology, histology and imaging, 
new ones include genomic, transcriptomics, epigenetics/ 
imprintomics, proteomic and metabolomics (so called “om-
ics”) [5-7]. The application of omics is ever more fundamen-
tal to investigate basis, causes and processes of death at the 
molecular level in the so called “molecular autopsy”. These 
innovative forensic procedure, hand in hand with the ad-
vances in medical sciences, are important to promote sci-
entific interpretation and evidence-based assessment of indi-
vidual deaths. 
1.2. Emerging Fields of Interest in Forensic Pathology 
 Molecular forensic pathology involves the application of 
medical sciences and all the available ancillary procedures 
for comprehensive assessment and complete interpretation of 
forensic matters [8]. Furthermore, experimental and practical 
investigations in molecular autopsy, i.e. molecular biological 
procedures derived from omic sciences in the context of fo-
rensic pathology, are usefulness in detecting basis, causes 
and mechanisms involved in the death process. These up-
dated procedures may effectively be included in routine in-
vestigation in combination with classical post-mortem diag-
nostic procedures, for a comprehensive assessment of the 
human death process, investigating this processes at a mo-
lecular level, as a useful resource in the determination of 
causes and manners of death, especially in unexpected sud-
den deaths [9-11]. 
 In addition to the identification of biological materials on 
the crime scene, lastly these procedures may also contribute 
to estimating the time of death and post-mortem interval 
(PMI), which is another major interest in forensic pathology, 
even if limited to cases in the early post-mortem period 
without evident decomposition. 
1.3. Role of Omics 
 In molecular forensic pathology, the individual genetic 
set (genome), the regulation of gene expression (transcrip-
tome) and the complement of genes’ products (proteome), 
are becoming, time after time, fundamental matters in order 
to investigate causes and manners of death. 
 In this way, omic sciences are bringing promising results. 
In particular, genomic and SNP (single nucleotide polymor-
phism) study is useful in the diagnosis and detection of pre-
disposing conditions to fatal thromboembolic and hyperten-
sive events, and in the determination of genetic variants re-
lated to sudden death, such as congenital long QT syndromes. 
On the other hand, transcriptomic and miRNAs analysis is use-
ful to demonstrate vitality of lesions; as long as proteomic 
approach presents many applications in pathology forensic, 
in particular in forensic investigations on crime scenes, for 
the identification of a biological matrix and the species of 
origin of a forensic trace without destruction of the DNA. 
2. GENOMICS 
 Genomics is the systematic study of genome, the total 
DNA containing 3.2 billion bases, with an estimated 30.000–
40.000 protein-coding genes and a variability of genetic ma-
terial between any two individuals approximately 1%. These 
genetic variations can be classified into four classes: 
• VNTR (variable number of tandem repeat); 
• STR (short tandem repeat); 
• SNP (single nucleotide polymorphism, including 
restriction fragment length polymorphism); 
• CNV (copy-number variation). 
 The most common variations in DNA sequences are sin-
gle nucleotide polymorphisms (SNPs), changes in a single 
base at a specific position in the genome, and in most cases 
with two alleles, found at a frequency of about 1:1000 bases. 
It is possible to distinguish: 
• SNPs in non-coding regions, altering the DNA se-
quence of promoter, introns or 3’-untraslated re-
gion; these changes may result in deregulation of 
gene expression affecting the amount or the struc-
ture of the encoded protein; 
• SNPs in coding regions, altering the DNA se-
quence of exons. Such nucleotide substitutions are 
called synonymous (no change of amino acid in the 
protein, but can affect stability of the transcript) or 
non-synonymous substitutions. Non-synonymous 
substitutions can be missense, if the change results 
in a different amino acid in the protein sequence 
(thus affecting protein functionality) or non-sense, 
if the change introduces a stop codon, causing a 
truncated and usually non-functional protein prod-
uct. 
 Being the most frequent and studied type of genetic inter-
individual variance, SNPs detection actually represents the 
heart of PM [12-19]. The importance of SNPs in forensic 
molecular pathology relies on the ability to recognize a ge-
netic predisposition to a condition which causes or contrib-
utes to death, as in the cases (described below) of risk as-
sessment of fatal thromboembolic and hypertensive events, 
and in the determination of genetic variants related to sudden 
death, such as congenital long QT syndromes. 
 Moreover, SNP profiling appears useful to establish the 
individual predisposition to suffer from adverse reaction, 
including lethal ones to drug intake. The role played by 
SNPs and other genetic variants in drug metabolism is stud-
ied by pharmacogenomics (PGx). Variations in genes coding 
for drug targets, drug metabolizing enzymes and drug trans-
porters are known to affect the susceptibility to both thera-
peutic and toxic effect of medication and other xenobiotics. 
Thus, also conventional dose consumption may lead to drug 
overload or to enhanced drug elimination (impairing thera-
peutic effect), both conditions possibly involved in adverse 
events causing death [20-22]. 
 Technologies for SNPs analysis range from low through-
put platforms, e.g. allowing characterization of one or few 
SNPs per run, as RFLP analysis, real-time PCR, pyrose-
quencing, to medium and high throughput assays, e.g. allow-
ing analyses of tens to hundreds SNPs per run, as MALDI-
ToF(matrix-assisted laser/desorption ionization-time of 
flight) mass spectrometry, microarray and next generation 
sequencing. Several SNP genotyping technologies facilitate 
rapid testing performed by automated platforms, some with 
FDA - Center for Devices and Radiological Health (CDRH) 
approval [23] (Table 1).  
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Table 1. List of Human Genetic Tests approved by CDRH – FDA US. 
xTAG CYP2D6 Kit v3 
Spartan RX CYP2C19 Test System 
Verigene CYP2C 19 Nucleic Acid Test 
INFINITI CYP2C19 Assay 
Invader UGT1A1 Molecular Assay 
Roche AmpliChip CYP450 microarray 
eSensor Warfarin Sensitivity Saliva Test 
eQ-PCR LC Warfarin Genotyping kit 
eSensor Warfarin Sensitivity Test and XT-8 Instrument 
Gentris Rapid Genotyping Assay - CYP2C9 & VKORCI 
INFINITI 2C9 & VKORC1 Multiplex Assay for Warfarin 
Drug metabolizing enzymes 
Verigene Warfarin Metabolism Nucleic Acid Test and Verigene System 
Invader Factor V 
Invader Factor II 
Illumina VeraCode Genotyping Test for Factor V and Factor II 
eSensor Thrombophilia Risk Test, eSensor FII-FV Genotyping Test, eSensor Fll Genotyping Test, eSensor FV Genotyp-
ing Test, eSensor MTHFR Genotyping Test 
Xpert HemosIL FII & FV 
Verigene F5 Nucleic Acid Test, Verigene F2 Nucleic Acid Test, Verigene MTHFR Nucleic Acid Test 
INFINITI System 
Factor II (Prothrombin) G20210A Kit 
Factor V leiden Kit 
Coagulation Factors 
Invader MTHFR 677, Invader MTHFR 1298 
Affymetrix CytoScan Dx Assay 
AneuVysion 
CEP 8 Spectrumorange DNA Probe Kit 
Chromosome abnormalities 
CEP X SpectrumOrange/ Y SpectrumGreen DNA Probe Kit 
 
2.1. Risk Assessment of Fatal Thromboembolic and Hy-
pertensive Events 
 Venous thromboembolism (VTE), with its main manifes-
tations - deep venous thromboembolism (DVT) and fatal 
pulmonary embolism (PE) -, is a multifactorial disease and is 
among the most common causes of natural unexpected death. 
Most deaths are associated with the three predisposing fac-
tors described by Virchow: stasis, hypercoagulability and 
vascular injury. In particular, hypercoagulability risk factors 
include thrombophilic diseases or conditions associated with 
an increased thrombotic risk.  
 The association between several SNPs and an increased 
individual risk for developing venous thromboembolism has 
been widely described and VTE-associated SNPs are in-
creasingly been employed to improve risk assessment of 
patients [24].  
 In forensics, a molecular pathology approach aimed to 
characterize the genomic risk of VTE is useful to improve 
the comprehension of basis, causes and mechanisms in-
volved in the death process involving thromboembolic 
events, according to an evidence-based approach to death 
assessment [25-28]. 
 It is noteworthy to note that the identification of a ge-
nomic profile contributing to a lethal VTE event may prompt 
the decedent’s relatives to check their own genomic profile 
and global VTE risk, warning for the onset of appropriate 
prevention strategies and thus avoiding a recurring tragedy 
within family [29-30]. 
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 Table 2 reports the main SNPs associated with increased 
risk of thrombophilia and having an important causal rele-
vance in causation of death [31-33]. Factor V Leiden, 
prothrombin or factor II (PT), plasminogen activator inhibi-
tor-1 (PAI-1), fibrinogen beta chain (FGB) and factor XIII 
A1 chain (F13A1) are particularly relevant since their altera-
tion is considered a direct risk factor and their activity can be 
assessed also post-mortem. 
 On the other hand, the polymorphisms in the genes en-
coding for methylenetetrahydrofolate reductase (MTHFR), 
cystathionine beta synthase (CBS), methionine synthase 
(MTR), methionine synthase reductase (MS_MTRR), repre-
sent indirect risk factors for thromboembolism (by decreased 
enzyme activity and hyperhomocysteinemia) and thus are 
less relevant. 
 For example, the SNPs of MTHFR gene, rs1801133 - 
also known as MTHFR C677T or A222V - and rs1801131 - 
also known as MTHFR A1298C or E429A - have as a result 
a more thermolabile enzyme, determining an activity re-
duced by 50%, that results in clinical phenotype with mild 
hyperhomocysteinemia, especially in nutritional deficiency 
of folic acid, with increased risk of cerebrovascular (stroke) 
and cardiovascular (myocardial infarction) events and ve-
nous thrombosis. However, the genetic risk factor may be 
counterbalanced with opportune therapy and dietary regi-
men, modifying the levels of homocysteine that however 
cannot be assessed in post-mortem, so that cannot be consid-
ered a major (direct) risk factor [34, 35]. 
 Instead, polymorphisms in FV Leiden and Prothrombin - 
Factor II genes are thought to be a major risk factor for 
thromboembolic events. The Factor V gene polymorphism 
known as Leiden mutation (rs6025, also termed F5L or 
G1691A) is found in 3 to 5% of the individuals. Risks for 
venous thromboembolism for (A;G) and (A;A) genotypes are 
2.7x and 18x, respectively; overall, patients heterozygotes 
for both Leiden and prothrombin SNP rs1799963 (also 
known as PT G20210A) have a higher risk of recurrent 
thrombosis, and depending on other factors (oral contracep-
tives, estrogen-progestogen therapy, pregnancy, surgical 
events or fractures, other prothrombotic disorders such as 
SLE, malignancy, ATIII deficiency, protein C or protein S), 
this risk can climb to at least 5x [36]. 
 Other important SNPs raising the risk of developing ve-
nous thromboembolism are: 
• Plasminogen activator inhibitor-1 PAI-1 gene in-
sertion/deletion results in increased plasma levels 
of PAI-1 (inhibitor of tPA) in homozygous carriers 
(4G/4G, 26% of the population); 
Table 2. Polymorphisms involved in thrombophilic risk. 
 Gene Name Chromosomal Location Mutation/SNP Researched 
MTHFR C677T 
(rs1801133) Methylenetetrahydrofolate reductase 
(MTHFR) 
1p36.22 
MTHFR A1298C 
(rs1801131) 
CBS C699T 
(rs234706) Cystathionine beta synthase 
(CBS) 
21q22.3 
CBS T1080C 
(rs5742905) 
Methionine synthase 
(MTR) 
1q43 
MTR A2756G 
(rs1805087) 
In
di
re
ct
 R
is
k 
Fa
ct
or
s 
Methionine Synthase Reductase 
(MS_MTRR) 
5p15.31 
MS_MTRR A66G 
(rs1801394) 
F5L G1691A 
(rs6025) Factor V 
(F5) 
1q24.2 
F5 G1764A 
(rs6030) 
Prothrombin - Factor II 
(PT) 
11p11.2 
PT G20210A 
(rs1799963) 
Plasminogen activator inhibitor-1 
(PAI-1) 
7q22.1 
PAI-1 -675(4G/5G) 
(rs1799889) 
Fibrinogen beta chain 
(FGB) 
4q31.3 
FGB G455A 
(rs1800790) 
D
ir
ec
t R
isk
 F
ac
to
rs
 
Factor XIII A1 chain 
(F13A1) 
6p25.1 
F13A1 Val34Leu 
(rs5895) 
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• Fibrinogen beta chain FGB G455A polymor-
phism increases the blood concentration of beta fi-
brinogen; 
• Factor XIII A1 chain gene Val34Leu polymor-
phism determines high concentrations of fibrinogen 
and increased permeability of the clot. 
 All these predisposing conditions result in greater risk of 
thrombosis, both arterial (myocardial infarction, coronary 
artery disease and youth cryptogenic cerebral stroke) and 
venous, complicated or not as thromboembolism, especially 
in smokers and hypertensives, mainly in the presence of envi-
ronmental risk factors trigger such as: long assets, fractures, 
surgeries, estrogen-progestogen therapy (oral contraceptive, 
replacement therapy in menopause). During pregnancy, this 
can cause various complications (such as miscarriage, 
preeclampsia, foetal growth retardation, abruptio placentae). 
 According to these premises, genotyping is indicated in: 
• All patients who experience events of venous 
thromboembolism, especially those younger (age 
<50 years) with unusual site of thrombosis (hepatic, 
mesenteric or cerebral), or who have recurrent 
thrombotic events; 
• All women who experience complications of preg-
nancy and those which, in the presence of a positive 
family history, must take estrogen-progestogen 
therapy; 
• Asymptomatic individuals who have a first-degree 
carrier of the mutation. 
 On the other hand, hypertension being one of the main 
risk factors for coronary disease, and hence also for sudden 
death, is 3x higher in patients with moderate hypertension 
than in normotensives, so in hypertensives, sudden cardiac 
death constitutes 27-60% of all cardiovascular deaths. 
 Gene polymorphisms predisposing to the development of 
hypertension have been described, the most important affect-
ing the genes coding for angiotensinogen (AGT), angiotensin 
II receptor type 1 (AGTR1), angiotensin converting enzyme 
(ACE) and integrin beta 3 (ITGB3 - HPA-1) (Table 3) [37, 38]. 
 SNPs in AGT gene have been implicated in risk for hy-
pertension and related disorders, such as heart disease and 
pre-eclampsia. In particular, patients with the mutated allele 
(C;T, C;C) of the SNP rs699 (also known as AGT T9543C) 
have a risk about 3x of developing cardiovascular diseases, 
whereas carriers of the polymorphic variant rs4762 (also 
known as AGT C9369T) have a greater risk of developing 
cardiovascular diseases and a 1.9x risk for pre-eclampsia 
[39, 40]. 
 AGTR1 gene is quite polymorphic, with over 50 de-
scribed SNPs affecting susceptibility to hypertension and 
related disorders, such as heart disease, as well as resistance 
to antihypertensive drugs. Polymorphism rs5186, also known 
as AGTR1 A1166C, in hypertensive patients correlates with 
increased aortic stiffness, risk of stroke and acute myocardial 
infarction [41-43]. 
 The insertion (I)/deletion (D) variant in the ACE gene 
can influence the degree to which individuals respond to 
ACE-inhibitors and the cardiovascular risk (hypertension, 
left ventricular hypertrophy, acute myocardial infarction at a 
young age and acute coronary syndrome in postmenopausal) 
for ID and DD genotype is 5x and 10x, respectively [44]. 
 At last, the ITGB3 gene polymorphism T1565C is asso-
ciated with a high risk of hypercoagulation, resulting in ve-
nous thrombotic complications [45]. 
2.2. Congenital Long QT Syndromes, Antipsychotics and 
Sudden Cardiac Death Diagnosis  
 Congenital long QT syndromes (LQTS) can arise from 
mutation of one of several genes and can be inherited in an 
autosomal dominant or recessive phenotype. Subsequently, 
QT interval is a heritable trait in healthy subjects and detect-
ing genetic variants is important for determining people at 
higher risk from drugs that cause QT prolongation. 
 Non-drug and environmental factors regulators of QT are 
female gender (because of shorter early repolarization and 
testosterone effects on calcium current), electrolyte distur-
bance (hypocalcaemia and hyperkalaemia), hypoglycaemia) 
and increasing age. QT prolongation is also associated with 
different pharmacological therapies, such as antipsychotics 
(in particular quetiapine, olanzapine, clozapine, sertindole, 
haloperidol and chlorpromazine), antidepressants (clomi-
pramine and amitriptyline, citalopram) and mood stabilizers 
(lithium), but not associated with anxiolytic agents. The risk 
of QT-prolonging is plasma concentration-related and depends 
on drug elimination (pharmacokinetic interactions) [46]. 
Table 3. Polymorphisms panel for hypertensive genomic profile. 
Gene Name Chromosomal Location Mutation/SNP Researched 
AGT T9543C 
(rs699) Angiotensinogen 
(AGT) 1q42.2 AGT C9369T 
(rs4762) 
Angiotensin II receptor type 1 
(AGTR1) 3q24 
AGTR1 A1166C 
(rs5186) 
Angiotensin converting enzyme 
(ACE1) 17q23.3 
ACE1 I/D 
(rs1799752) 
Integrin beta 3 - HPA-1 – GPIIIa 
(ITGB3) 17q21.32 
ITGB3 T1565C 
(rs5918) 
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 In particular, drug administration can induce Torsades de 
Pointes (diTdP), a specific form of ventricular arrhythmia, 
sustained by inhibition of the output currents of potassium 
channel IKr and by block of inner currents of sodium and 
calcium. Variants of LQTS may contribute to susceptibility 
for diTdP in a percentage on average around 5-10% of sub-
jects. Identification of these cases emphasizes the emerging 
role of preventive medicine [47-58]. 
 Fifteen different genetic mutations in ion channel 
subunits (potassium and sodium channels) and in regulatory 
protein have been identified (Table 4) [53-58]. 
 LQTS1, known as Jervell and Lange-Nielsen syndrome, 
is the most common form of LQST, representing 30-35% of 
all cases. The gene responsible is KCNQ1, which encodes 
alpha subunit of slow delayed rectifier potassium voltage-
gated channel (KV7.1). SNPs in KCNQ1 gene cause marked 
prolongation of the QT interval (due to the almost complete 
loss of IKr current), and an increased risk of ventricular ar-
rhythmias and congenital deafness. LQTS1 is less often as-
sociated with sudden death compared to LQTS2, so it is one 
of the less severe forms of LQTS. 
 LQTS2 is the second most common variant, representing 
25-30% of all cases and involving hERG gene, which en-
codes alpha subunit of rapid delayed rectifier potassium 
voltage-gated channel (KV11.1), part of the potassium rapid 
rectifying current (IKr). Most of the drugs that cause LQT 
block IKr current via hERG gene. 
 LQTS3 is determined by mutations in SCN5A gene, 
which encodes alpha-5 subunit of sodium voltage-gated 
channel (NaV1.5). Calcium has been suggested as a regulator 
of SCN5A protein. 
 Most updated and current studies investigate the relation-
ship of polymorphisms and variable risk for TdP. Between 
the discovered SNPs, the most common ones giving rise to 
alleles predisposing to LQTS are SCN5A Ser1103Tyr and 
KCNQ1 Ala341Val. 
 SCN5A Ser1103Tyr (rs7626962) is the most common 
polymorphism (∼13% allelic frequency in African Ameri-
cans), involving alpha-5 subunit of sodium voltage-gated 
channel (NaV1.5) and determining increased late sodium 
current especially under acidosis conditions, with suscepti-
bility to acidosis-induced arrhythmia and increased risk for 
sudden infant death syndrome [59, 60]. 
 KCNQ1 Ala341Val (rs12720459) represents one of the 
most common variants within the KCNQ1 gene leading to 
LQT1, the most frequent form of LQTS [61]. 
 This variant meets ACMG 2013 criteria regarding inci-
dental findings in exome or genome sequencing, as a variant 
that they do recommend informing a patient about. In par-
ticular, ACMG recommends the opportunity to re-evaluate 
the patient’s personal and family history and consider appro-
priate surveillance or intervention for patients and their fam-
ily members who are deemed to be at increased risk for these 
conditions. 
3. TRANSCRIPTOMICS 
 Transcriptomics is the study of the RNA present in the 
cell and thus analyses the panel of genes actively expressed. 
 MicroRNAs (miRNAs) are small endogenous non-coding 
single-stranded RNA molecules ~22 nucleotides long that 
can transcriptionally and post-transcriptionally regulate gene 
expression, interacting with almost 30% of the coding genes. 
In particular miRNAs, assembled into the RNA-induced si-
lencing complex (RISC), bind to their target messenger 
RNAs (mRNAs) in 3’ UTR, leading to mRNA degradation 
and blocking translation. 
 miRNAs have tissue-specific patterns of expression, are 
highly conserved across mammalian species and related to 
several diseases (cancer, diabetes, cardiovascular disease), 
becoming attractive therapeutic targets. miRNAs are increas-
ingly used in forensic pathology, in particular to demonstrate 
tissue or cell vitality in skin lesions [62-64]. 
3.1. Determination of Vitality and Age of Skin Lesions 
and Wounds 
 Study of miRNAs in the determination of the healing 
processes, and therefore, of formation time of a possible skin 
lesion, is an emerging practice in forensic pathology. 
 The repair process of damaged skin involves three 
phases: inflammatory, proliferative (epithelialization, angio-
genesis, granulation and collagen deposition) and remodel-
ling phase. During this process, changes take place in the 
expression of specific miRNAs at a specific phase of wound 
healing. Many miRNAs have been proposed as targets of 
investigation in the dating of the skin lesions. The most im-
portant are reported in Table 5. 
• Inflammation response to wound is tightly regulated 
by pro-inflammatory as well as anti-inflammatory 
signals. miRNAs are responsive and regulate some 
inflammatory mediators in the course of wound 
healing. In particular, miR-21, miR-146a/b and 
miR-155 play a key role. miR-146 and miR-155 are 
induced by TNF-α and IL-1β, while miR-21 is in-
duced by IL-6. miR-21 target are PTEN and PDCD4, 
miR-146 targets are IRAK and COX2, while miR-
155 target are SHIP1, SOCS1, and IL-12 [65, 66]. 
• Proliferation is characterized by epithelialization, 
angiogenesis, granulation and collagen deposition, 
and is influenced by hypoxia and hypoxia-sensitive 
miRNA (known as hypoxamiRs). miRNA-210, un-
der control of hypoxia-regulated genes Hif-1 α and 
Hif-2 α, is the most sensitive to hypoxia; on the 
other hand, miR-210 silences some key proteins 
like E2F3 which is required for keratinocyte prolif-
eration. Some of the most well-characterized 
miRNA-regulated proteins involved in proliferation 
are Spred1 (miR-126), c-kit (miR-221/222), Tsp-1 
(miR-17-92), ITGA5 (miR-92a), VEGF (miR-20a) 
and TIMP-1 (miR-17-5p) [67, 68]. 
• Remodelling phase is characterized by collagen 
deposition, and several miRNAs contribute to this 
phase, in particular miRNA-29b, miRNA-29c, and 
miRNA-192. MiRNA-29b and miR-29c targets are 
Smads and β-catenin, involved in scarless healing, 
while miR-192 target is Smad-interacting protein 1 
(SIP1) [69]. 
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Table 4. SNPs involved in congenital long QT syndromes. 
Type Protein Affected Chromosomal Location Gene 
Number of 
SNPs 
Most Common SNP  
Researched 
LQT1 
Alpha subunit of slow delayed rectifier potassium volt-
age-gated channel (KV7.1) 
11p15.5 KCNQ1 414 
KCNQ1 Ala341Val 
(rs12720459) 
LQT2 
Alpha subunit of rapid delayed rectifier potassium volt-
age-gated channel (KV11.1) 
7q35-q36 KCNH2 500 
KCNH2 Lys897Thr 
(rs1805123) 
LQT3 
Alpha 5 subunit of sodium voltage-gated channel 
(NaV1.5) 
3p21 SCN5A 545 
SCN5A Ser1103Tyr 
(rs7626962) 
LQT4 Anchor protein Ankyrin B 4q25-q27 ANK2 31 
ANK2 Arg1788Trp 
(rs121912706) 
LQT5 
Beta subunit MinK of slow delayed rectifier potassium 
voltage-gated channel (KV7.1) 
21q22.1-q22.2 KCNE1 31 
KCNE1 Asp76Asn 
(rs74315445) 
LQT6 Beta subunit MiRP1 of potassium voltage-gated channel 21q22.1 KCNE2 20 
KCNE2 Gln9Glu 
(rs16991652) 
LQT7 Inward rectifier potassium channel 2 (Kir2.1) 17q23.1-q24.2 KCNJ2 55 
KCNJ2 Asp71Val 
(rs104894575) 
LQT8 
Alpha 1C subunit of calcium voltage-gated channel 
(CaV1.2) 
12p13.3 CACNA1C 31 
CACNA1C Gly406Arg 
(rs79891110) 
LQT9 Caveolin 3 3p25 CAV3 42 
CAV3 Thr78Met 
(rs72546668) 
LQT10 Beta 4 subunit of sodium voltage-gated channel (NaV1.4) 11q23 SCN4B 4 
SCN4B Leu179Phe 
(rs121434386) 
LQT11 A-kinase anchor protein 9 7q21-q22 AKAP9 11 
KCNQ1 Ser1570Leu 
(rs121908566) 
LQT12 Alpha 1 syntrophin 20q11.2 SNTA1 4 
SNTA1 Ala257Gly 
(rs56157422) 
LQT13 
G protein-activated inward rectifier potassium channel 4 
(Kir3.4) 
11q24 KCNJ5 13 
KCNJ5 Gly387Arg 
(rs199830292) 
LQT14 Calmodulin 1 14q32.11 CALM1 7 
CALM1 Asp130Gly 
(rs730882252) 
LQT15 Calmodulin 2 2p21 CALM2 6 
CALM2 Asp96Val 
(rs730882254) 
 
4. PROTEOMICS 
 Proteome is the set of all expressed proteins (>100.000 
proteins) in a specific cell and in a specific stage, reflecting 
both genes expression and environment influence, thus hold-
ing special promise for biomarker discovery because of the 
ubiquitously involvement in pathological processes [70]. 
 The main advantage of proteomics markers compared to 
genomic and transcriptomics markers is that they are more 
closely related to the actual phenotype. 
 Proteomic approach presents many applications in foren-
sic pathology, in particular in forensic investigations on 
crime scenes, for the identification of biological matrices and 
the origin species of a forensic trace without destruction of 
the DNA [71]. 
4.1. Detection of Biological Specimens on the Crime 
Scene 
 Proteomic-based approach has been developed to identify 
protein on the crime scene (blood, seminal fluid, saliva and 
lacrimal fluid). Even if proteins are less stable than DNA, the 
most remarkable advantage of this approach is to not be de-
structive, by the first washing step of DNA extraction, thus 
saving most of the sample for subsequent DNA analysis 
[72]. 
 The proteomic approach ranges from identification of 
single proteins by immunohistochemistry to simultaneous 
identification of multiple protein signatures using mass spec-
trometry technology as MALDI, surface-enhanced laser 
desorption/ionisation (SELDI), capillary liquid chromatogra-
phy coupled to tandem mass spectrometry (LC-MS/MS). 
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Table 5. Key miRNAs involved in different phases of wound healing. 
Phase MicroRNA Target 
miR-21 PTEN, PDCD4 
miR-105 TLR2 
miR-140 PDGF receptor 
miR-146 IRAK, COX2 
miR-146a, miR-125b TNF-alfa 
miR-147 IgG FcγRI (CD64) 
miR-155 SHIP1, SOCS1, IL12 
Inflammatory 
miR-424 PU.1, NFI-A 
miR-15b, miR-16, miR-20a, miR-20b VEGF 
miR-17 Janus Kinase 1 
miR-17-5p TIMP1 
miR-17-92 TSP-1, CTGF 
miR-92a Integrin-alfa5 
miR-126 Spred1, PIK3R2 
miR-130a GAX, HOXA5 
miR-184 Akt 
miR-205 SHIP2, Rho-ROCK1 
miR-210 EFNA3, E2F3, ISCU 1/2 
miR-221, miR-222 c-kit 
miR-296 HGS 
miR-320 IGF-1 
Proliferative 
miR-378 Fus-1, Sufu 
miR-29a Type I-II collagen 
miR-29b, miR-29c Smads, beta-catenin Remodelling 
miR-192 SIP1 
 
 Scientific investigations on biological traces occurring on 
a crime scene are usually carried out through a series of se-
quential steps, involving generic, species, regional and indi-
vidual diagnosis. All these steps together allow the investiga-
tors to reconstruct the dynamics of the criminal event and to 
check the reliability of assertions by putative suspect people 
[73-75]. In particular, in generic and species diagnosis, pro-
teomic procedures can be applied: 
• Generic diagnosis: consists of the identification of 
real nature of the trace (saliva, blood, semen and 
lacrimal fluid) by using preliminary and confirma-
tory tests. Preliminary tests include luminol or 
benzidine for blood, ultraviolet light or other light 
sources at specific wavelengths for semen and sa-
liva. Confirmatory tests are essentially based on 
immunochemical techniques or ELISA methods, 
detecting prostate-specific antigen (PSA) in semen, 
alpha-amylase 1 in saliva and alpha-amylase 2, in 
semen and vaginal secretion. 
• Species diagnosis: consists of the determination of 
species of the donor of trace found at a crime scene. 
Previously performed by highly specific antibodies 
on blood and on hair by microscopic examination, 
new MS-based proteomic procedures have been in-
troduced to obtain species diagnosis and the identi-
fication of human body fluids or tissues. Most im-
portant protein markers of species diagnosis detected 
by capillary LC-MS/MS are reported in Table 6. 
 This proteomic approach has many advantages such as 
the possibility to identify proteins by their fragments, high 
specificity of tissue localization and high sensitivity of LC-
MS/MS. Instead, disadvantages arising from the intrinsic 
nature of biological traces to be analysed are represented by 
easy degradation of biological matrices, low variability so 
that no individual diagnosis is possible, no possibility of am-
plification and quantity problems [76-78]. 
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Table 6. Protein markers in biological matrices for species 
diagnosis. 
Matrices Protein Markers 
Haemoglobin Alpha-subunit (HBA) 
Haemoglobin Beta-subunit (HBB) 
Band 3 anion transport protein (SLC4A1) 
Alpha-Haemoglobin-Stabilizing Protein (AHSP) 
Glycophorin-A (GLYA) 
Porphobilinogen deaminase (PBGD) 
Alpha-spectrin (SPTA1) 
Blood 
Beta-spectrin (SPTB) 
Sweat Dermcidin (DCD) 
Lacrimal proline-rich protein 4 (LPRR4) 
Lacrimal Androgen-binding protein delta (LABPD) 
Lacrimal Androgen-binding protein zeta (LABPZ) 
Lacrimal 
fluid 
Extracellular glycoprotein lacritin (LACRT) 
Alpha-amylase 1 (AMY1) 
Histatin-1 (HTN1) 
Histatin-3 (HTN3) 
Basic salivary proline-rich protein 2 (PRB2) 
Statherin (STATH) 
Mucin-5B (MUC5B) 
Saliva 
Cystatin SA (CST2) 
Urine Uromodulin (UMOD) 
Matrix metalloprotease 7 (MMP7) 
Matrix metalloprotease 10 (MMP10) Menstrual blood 
Matrix metalloprotease 11 (MMP11) 
Mucin 4 isoform A (MUC4) 
Human Beta-Defensin 1 (HBD1) 
Small Proline-Rich Protein 3 (SPRP3) 
Dimethylaniline Monooxygenase 3 (FMO3) 
Cartilage Intermediate Layer Protein (CILP) 
Beta-Crystallin S (CRYGS) 
Vaginal 
fluid 
A-Kinase Anchor Protein 13 Isoform 1 (AKAP13) 
Semenogelin-1 (SEMG1) 
Semenogelin-2 (SEMG2) 
Prostate-Specific Antigen (PSA) 
Prostatic acid phosphatase (PAP) 
Mucin 6 (MUC6) 
Kallikrein 4 (KLK4) 
Protamine 1 (PRM1) 
Protamine 2 (PRM2) 
Progestogen-Associated Endometrial Protein (PAEP) 
Cysteine-Rich Secretory Protein 1 (CRISP1) 
Seminal 
fluid 
Transglutaminase 4 (TGM4) 
 
CONCLUSION 
 Application of omic sciences to investigate the processes 
of death at a biological molecular level in the context of fo-
rensic pathology is an emerging practice. The aim to visual-
ize molecular evidence for a general explanation of the hu-
man death involving forensic issues, as well as for the as-
sessment of individual death, makes this new approach even 
more fundamental. The new opportunities, offered by omics, 
are of considerable interest to forensic scientists. So that, 
these procedures have been and will even be more in the 
coming decades incorporated in routine death investigations. 
This new challenge in forensic research has, in fact, become 
an increasingly important tool in medical examiners’ arma-
mentarium in determining cause of death or contributing 
factors to death. 
 For example, understanding the genetic component of the 
common disease, coupled with the use of molecular genetic 
testing, has become an increasingly important issue. The 
most recent advances in “molecular autopsies” have begun to 
uncover the mystery surrounding sudden unexplained natural 
deaths by identifying mutations that can result in or predis-
pose an apparently healthy individual to sudden death. Al-
though a relatively novel concept in the forensic context, 
omic sciences have the capability to assist in the interpreta-
tion of deaths. Advanced diagnostic analyses, genetic coun-
selling, and interdisciplinary and multidisciplinary approach, 
should be integral parts of forensic practice. 
 In this way, the ability to identify underlying cause of 
death, especially in genetic disorders, not only allows the 
determination of cause of death in a decedent, but may also 
help in avoiding a recurring tragedy within family. Large 
population data and large-scale clinical trials can provide a 
powerful resource for assessing the inherent risk, providing 
an opportunity to investigate genomic associations and 
common inherited variations in the individuals. So on, post-
mortem human data can also contribute to understanding 
patients’ critical conditions in clinical management. The po-
tential to improve the clinical practice is only at the very 
beginning but will present an important biomedical tool in 
the omic era. 
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